Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29768547 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL16893543 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL20646293 | 0.93 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL20646281 | 0.91 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL16893929 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL16893930 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL20646261 | 0.90 | PTGS2 (0.94) | PTGS2PTGS1 | |
| SCHEMBL20646263 | 0.87 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL20921390 | 0.87 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL16893551 | 0.85 | PTGS2 (0.74) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3094333-B1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2020-10-14 | — | — | EP | claimed |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | Euclises Pharmaceuticals, Inc. (US) | 2019-04-23 | — | — | US | claimed |
| EP-3400218-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. (US) | 2018-11-14 | — | — | EP | claimed |
| WO-2017120591-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. (US) | 2017-07-13 | — | — | WO | claimed |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2017-07-13 | — | — | US | claimed |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. | 2016-11-24 | — | — | US | claimed |
| EP-3094333-B1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | Euclises Pharmaceuticals, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | Euclises Pharmaceuticals, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2017-07-13 | — | — | US | disclosed |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2017-07-13 | — | — | US | disclosed |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | Euclises Pharmaceuticals, Inc. | 2017-07-13 | — | — | US | disclosed |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. | 2016-11-24 | — | — | US | disclosed |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | Euclises Pharmaceuticals, Inc. | 2016-11-24 | — | — | US | disclosed |
| CN-106102747-A | NO-releasing nitrooxy-chromene conjugates | 欧利瑟斯制药公司 | 2016-11-09 | — | — | CN | disclosed |
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197500-A1 | NO-RELEASING GUANIDINE-CHROMENE CONJUGATES | ARG1, ARGLU1, CGAS | PTGS2 1336/4885PTGS1 901/4885 |
| US-10266511-B2 | No-releasing nitrooxy-chromene conjugates | NOS1, NOS2, NOS3 | PTGS2 608/4885PTGS1 209/4885 |
| US-20160340330-A1 | NO-RELEASING NITROOXY-CHROMENE CONJUGATES | NOS1, NOS2, NOS3 | PTGS2 608/4885PTGS1 209/4885 |
| US-20170196835-A1 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT | CD274, ICOS, PDCD1 | PTGS2 3149/4885PTGS1 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.